Invesco Ltd. purchased a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 74,440 shares of the company's stock, valued at approximately $187,000. Invesco Ltd. owned about 0.26% of Aerovate Therapeutics at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. bought a new position in shares of Aerovate Therapeutics during the 4th quarter valued at $1,590,000. Deltec Asset Management LLC increased its position in Aerovate Therapeutics by 86.4% during the first quarter. Deltec Asset Management LLC now owns 361,804 shares of the company's stock worth $908,000 after buying an additional 167,680 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in Aerovate Therapeutics during the fourth quarter valued at about $159,000. BNP Paribas Financial Markets acquired a new stake in shares of Aerovate Therapeutics in the fourth quarter worth about $145,000. Finally, Two Sigma Advisers LP increased its position in Aerovate Therapeutics by 38.5% during the fourth quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after acquiring an additional 42,700 shares during the period.
Aerovate Therapeutics Stock Down 0.6%
Aerovate Therapeutics stock traded down $0.05 during mid-day trading on Thursday, reaching $7.58. The company had a trading volume of 35,897 shares, compared to its average volume of 12,438. Aerovate Therapeutics, Inc. has a 52 week low of $56.35 and a 52 week high of $105.00. The company has a 50 day moving average of $8.30 and a 200-day moving average of $35.06. The firm has a market cap of $219.56 million, a price-to-earnings ratio of -2.53 and a beta of 0.95.
About Aerovate Therapeutics
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
